September 04, 2018 Zelluna joins the adoptive cell therapy chase As the tiny Norwegian biotech gears up to put its first asset into the clinic, investors could use an ongoing trial to handicap its chances of success.
March 17, 2017 Snippet roundup: Medica and Cell Medica are in the money, but Endo and Valeant feel the pain
